Kamen determines what is clinically appropriate for you after your evaluation and labs, and we are transparent with you about exactly which medication you are receiving and why
According to FDA labeling, nausea occurs in approximately 44% of patients on Wegovy (2.4 mg for weight management) and 15-20% on lower diabetes doses, with vomiting, diarrhea, constipation, and abdominal pain also common
However, in a retrospective cohort study of electronic health records of 240,618 patients with overweight or obesity who were prescribed semaglutide or non-GLP-1 receptor agonist antiobesity medication and 1,589,855 patients with type 2 diabetes prescribed semaglutide or non GLP-1 receptor agonist hypoglycaemic treatment, during six-month follow up after initiation of treatment, there was lower risk of suicidal ideation in patients prescribed semaglutide regardless of whether there was a history of previous suicidal ideation
rare does not mean ignorable